Core Insights - OrthoPediatrics Corp. has gained distribution rights to introduce additional bracing solutions in the US market through its OrthoPediatrics Specialty Bracing (OPSB) division [1][2] Company Overview - OrthoPediatrics is dedicated to advancing pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions [3] - The company currently markets over 70 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [3] - OrthoPediatrics distributes its products in the United States and over 70 countries globally [3] New Product Offerings - The OPSB division has established a distribution agreement with Thrive Orthopedics LLC, focusing on three pediatric orthotic solutions [2] - The Thrive Orthopedics F3 Hero Pediatric AFO is a lightweight carbon fiber ankle foot orthosis designed to improve walking stability while allowing flexibility [2] - The TruStretch Pediatric Equinus Brace provides optimal stretching for children with equinus deformity [2] - The Thrive Pediatric X-Glide Carbon Fiber Insoles are available in both rigid and flexible styles for gait training [2] Leadership Commentary - Joe Hauser, President of the OPSB division, expressed pride in the advancements made to help children with non-operative care and highlighted the distribution agreement as a significant step in the company's growth strategy [3]

Core Insights - OrthoPediatrics Corp. achieved record full year 2024 revenue of $205 million, reflecting a 38% year-over-year growth [1][6] - The company initiated guidance for adjusted EBITDA in 2025, projecting between $15 million to $17 million [3][4] 2024 Business and Financial Highlights - The preliminary unaudited full year 2024 net revenue is $204.7 million, up from $148.7 million in 2023, marking a 38% increase [6] - Domestic net revenue for 2024 is expected to be $161.1 million, representing a 45% annual growth, while international net revenue is projected at $43.6 million, a 16% annual growth [6] - In Q4 2024, the company generated preliminary unaudited net revenue of $52.7 million, a 40% increase from $37.6 million in Q4 2023 [6] - Domestic Q4 net revenue is expected to be $42.9 million, reflecting a 52% growth year-over-year, while international net revenue is projected at $9.8 million, a 5% increase [6] 2025 Financial Guidance - OrthoPediatrics projects 2025 revenue to be between $235 million and $242 million, indicating a growth of 15% to 18% compared to 2024 [3] - The company anticipates annual set deployment to be approximately $15 million [3] Strategic Initiatives and Market Position - The company continues to grow its market share in pediatric orthopedics, with strong performance in its Trauma and Deformity and Scoliosis businesses [4] - The specialty bracing business has been identified as a significant market opportunity, with plans for expansion and scaling in the coming years [4] Company Overview - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 70 products across trauma and deformity, scoliosis, and sports medicine categories [10] - The company distributes its products in the U.S. and over 70 countries globally [10]

Core Insights - OrthoPediatrics Corp. achieved record full year 2024 revenue of $205 million, reflecting a 38% year-over-year growth compared to $148.7 million in 2023 [1][6] - The company projects 2025 revenue to be between $235 million and $242 million, indicating a growth of 15% to 18% compared to 2024 [3] - OrthoPediatrics expects to generate adjusted EBITDA of $15 million to $17 million for the full year 2025 [3] 2024 Business and Financial Highlights - The company helped over 34,000 children in Q4 2024, totaling over 1.1 million children since inception [6] - Preliminary unaudited Q4 2024 net revenue reached $52.7 million, a 40% increase from $37.6 million in Q4 2023 [6] - Domestic Q4 2024 net revenue is expected to be $42.9 million, representing a 52% growth year-over-year, while international net revenue is projected at $9.8 million, a 5% increase [6] Strategic Initiatives - The Trauma and Deformity and Scoliosis businesses are key contributors to the company's growth, with a strong performance in the specialty bracing (OPSB) business [4] - The company aims to expand and scale its OPSB business, viewing it as a significant market opportunity and a strategic catalyst for growth [4] - OrthoPediatrics plans to release detailed Q4 and full year 2024 financial results in early March, with preliminary figures subject to adjustment [4]

WARSAW, Ind., Jan. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the rapid expansion of its Specialty Bracing (OPSB) division with entrance into 3 target markets within Indiana, Colorado, and Florida. Each of these new locations broadens the Company’s position in targeted geographies to partner with pediatric orthopedic surgeons in the region to treat chil ...

WARSAW, Ind., Dec. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics today announced that the OrthoPediatrics Specialty Bracing (OPSB™) division is expanding its product offering with the launch of two new products including the OPSB Sensor System and MOVE-D™. The OPSB Sensor System represents the first sensor solution in OrthoPediatrics’ portfolio and an important step forward ...

WARSAW, Ind., Nov. 26, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company dedicated exclusively to advancing the field of pediatric orthopedics, is excited to announce significant updates to the DF2® Brace, a cornerstone product within the OrthoPediatrics Specialty Bracing business (“OPSB”). The DF2 Brace updates include expanded indications for use, enhanced sizing options, and additional international markets. The DF2 Brace, which has seen strong ...

OrthoPediatrics Corp. (NASDAQ:KIDS) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Trip Taylor - Gilmartin Group David Bailey - President & Chief Executive Officer Fred Hite - Chief Financial Officer & Chief Operating Officer Conference Call Participants Matt O'Brien - Piper Sandler Joseph Conway - Needham & Company Operator Good morning and welcome to OrthoPediatrics Corporation's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-38242 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) | --- | --- | --- | |--- ...

For the quarter ended September 2024, OrthoPediatrics (KIDS) reported revenue of $54.57 million, up 36.5% over the same period last year. EPS came in at -$0.18, compared to -$0.13 in the year-ago quarter. The reported revenue represents a surprise of +1.21% over the Zacks Consensus Estimate of $53.92 million. With the consensus EPS estimate being -$0.12, the EPS surprise was -50.00%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.13 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this maker of orthopedic devices would post a loss of $0.31 per share when it actually produced a loss of $0.23, delivering a surprise of 25.81%. Over the last four quarters, the c ...